Suchergebnisse - "Haiderali, Amin"

PubPharm (51)

1

Pembrolizumab plus chemotherapy for first-line treatment of advanced triple-negative breast cancer

enthalten in: Future oncology (London, England) | 2024

von Haiderali, A. | Huang, M. | Pan, W. | +3

2

Association between event-free survival and overall survival in early-stage triple-negative breast cancer

enthalten in: Future oncology (London, England) | 2024

von Huang, M. | Fasching, P. | Haiderali, A. | +7

3

Cost-Effectiveness of Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab in Patients with High-Risk, Early-Stage, Triple-Negative Breast Cancer in Switzerland

enthalten in: PharmacoEconomics - open | 2024

von Favre-Bulle, A. | Huang, M. | Haiderali, A. | +1

4

Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer : results from the phase 3 randomised KEYNOTE-119 study

enthalten in: European journal of cancer (Oxford, England : 1990) | 2023

von Schmid, P. | Lipatov, O. | Im, S. | +18

5

Health-Related Quality of Life With Pembrolizumab+Chemotherapy Versus Placebo+Chemotherapy for Advanced Triple-Negative Breast Cancer : KEYNOTE-355

enthalten in: Journal of the National Cancer Institute | 2023

von Cescon, D. | Schmid, P. | Rugo, H. | +16

6

Cost-Effectiveness of Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab in Patients with High-Risk, Early-Stage, Triple-Negative Breast Cancer in Switzerland

enthalten in: PharmacoEconomics - open | 2023

von Favre-Bulle, A. | Huang, M. | Haiderali, A. | +1

7

Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer : a systematic review and network meta-analysis

enthalten in: BMC cancer | 2023

von Cortes, J. | Haiderali, A. | Huang, M. | +7

8

Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis

enthalten in: BMC cancer | 2023

von Cortes, J. | Haiderali, A. | Huang, M. | +7

9

Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis

enthalten in: BMC cancer | 2023

von Cortes, J. | Haiderali, A. | Huang, M. | +7

10

Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States

enthalten in: Advances in therapy | 2023

von Huang, M. | A Fasching, P. | Haiderali, A. | +9

CommentIn: Adv Ther. 2023 Sep;40(9):4111-4113. - PMID 37432550

1
2
3
4
5
6
Nächster »
[6]